NDC11 00469067711
This exact 11-digit normalized identifier can correspond to more than one FDA hyphenation. FDA.report preserves the exact identifier and exposes every structurally valid candidate without guessing.
Possible FDA NDC forms#
| Package NDC | Product root |
|---|---|
| 00469-0677-11 | 00469-0677 |
| 00469-677-11 | 00469-677 |
| 0469-0677-11 | 0469-0677 |
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 0469-0677 | 0469-0677-11 | D | Discontinued by firm | 2026-08-10 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ASTAGRAF XL | TACROLIMUS EXTENDED-RELEASE CAPSULES | Astellas Pharma US, Inc. | 550a5cd4-fbf2-4c09-b577-6bde8fcbdf6e | 2026-01-14 | Boxed warning, Warnings, Adverse reactions | 0469-0677-11 0469-0677 00469067711 |